GenoFocus, Inc.

KOSDAQ:A187420 Stock Report

Market Cap: ₩102.7b

GenoFocus Past Earnings Performance

Past criteria checks 2/6

GenoFocus has been growing earnings at an average annual rate of 4.5%, while the Chemicals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 14.7% per year. GenoFocus's return on equity is 12.5%, and it has net margins of 3%.

Key information

4.5%

Earnings growth rate

5.2%

EPS growth rate

Chemicals Industry Growth13.9%
Revenue growth rate14.7%
Return on equity12.5%
Net Margin3.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price Jump

Oct 29
There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price Jump

GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of Debt

Aug 05
GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of Debt

Is GenoFocus (KOSDAQ:187420) A Risky Investment?

Apr 13
Is GenoFocus (KOSDAQ:187420) A Risky Investment?

Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?

Feb 16
Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?

Is GenoFocus (KOSDAQ:187420) A Risky Investment?

Dec 22
Is GenoFocus (KOSDAQ:187420) A Risky Investment?

Revenue & Expenses Breakdown

How GenoFocus makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A187420 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2434,8341,0452,0798,929
30 Jun 2432,197-2,8563,90311,021
31 Mar 2428,048-1,4443,83510,997
31 Dec 2327,008-2,9504,02511,608
30 Sep 2325,340-15,8795,88213,050
30 Jun 2325,467-13,6684,35611,891
31 Mar 2327,827-13,7064,47612,147
31 Dec 2227,802-12,9684,23011,681
30 Sep 2227,274-8,8374,18311,541
30 Jun 2227,140-8,6413,71611,457
31 Mar 2226,427-8,2223,36011,570
31 Dec 2125,874-6,8172,91310,413
30 Sep 2122,921-10,3122,82810,370
30 Jun 2120,533-10,2982,5679,810
31 Mar 2119,258-13,0352,4518,274
31 Dec 2018,769-12,2172,3648,025
30 Sep 2018,853-5,1422,2905,922
30 Jun 2017,807-5,7292,1815,149
31 Mar 2016,287-5,9072,1894,983
31 Dec 1914,942-5,7592,1514,261
30 Sep 1912,878-5,9521,9753,401
30 Jun 1913,169-3,4271,9282,144
31 Mar 1912,388-3,0201,7671,202
31 Dec 1811,518-2,3231,808899
30 Sep 1811,592-431,649671
30 Jun 1811,1384331,645537
31 Mar 1811,6851,4571,772359
31 Dec 1711,5061,4111,594352
30 Sep 1710,9222,0441,589295
30 Jun 179,8952,2141,532360
31 Mar 178,0542,1231,302331
31 Dec 167,0291,6151,265265
30 Sep 166,5628741,188247
30 Jun 166,4611,2431,146124
31 Mar 166,6541,1871,071108
31 Dec 156,6401,211978136
30 Sep 158,4103,192910203
30 Jun 157,7962,569858208
31 Mar 156,7982,313860233
31 Dec 146,1482,182817244
31 Dec 132,404147444465

Quality Earnings: A187420 has a large one-off gain of ₩6.7B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A187420 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A187420 has become profitable over the past 5 years, growing earnings by 4.5% per year.

Accelerating Growth: A187420 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A187420 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (21%).

Return on Equity

High ROE: A187420's Return on Equity (12.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:00
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GenoFocus, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
In Pil KimCape Investment & Securities Co., Ltd.
Jong-Woo KimIBK Securities Co. Ltd.